Research Analysts Set Expectations for Exelixis Q3 Earnings

Key Points

• Zacks Research has lowered its Q3 2025 earnings per share estimate for Exelixis from $0.57 to $0.56, maintaining a "Hold" rating on the stock.
• Exelixis recently reported Q2 earnings of $0.75 per share, exceeding estimates, although revenue declined 10.8% year-over-year.
• The current consensus rating for Exelixis is "Moderate Buy," with an average price target of $44.42 from analysts.

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Equities researchers at Zacks Research reduced their Q3 2025 earnings per share (EPS) estimates for shares of Exelixis in a research note issued on Tuesday, October 7th. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings per share of $0.56 for the quarter, down from their previous estimate of $0.57. Zacks Research has a "Hold" rating on the stock. The consensus estimate for Exelixis' current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis' Q4 2026 earnings at $0.74 EPS, FY2026 earnings at $2.35 EPS, Q3 2027 earnings at $0.78 EPS and FY2027 earnings at $3.01 EPS.

Several other brokerages also recently issued reports on EXEL. JMP Securities reissued a "market outperform" rating and set a $50.00 target price on shares of Exelixis in a research note on Tuesday, July 29th. The Goldman Sachs Group assumed coverage on Exelixis in a research note on Wednesday, September 17th. They issued a "buy" rating and a $47.00 price objective on the stock. Stifel Nicolaus lifted their price objective on Exelixis from $38.00 to $41.00 and gave the stock a "hold" rating in a research note on Tuesday, July 29th. William Blair reaffirmed an "outperform" rating on shares of Exelixis in a research note on Tuesday, July 29th. Finally, HC Wainwright reduced their price objective on Exelixis from $53.00 to $46.00 and set a "buy" rating on the stock in a research note on Tuesday, August 12th. Fifteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $44.42.

Exelixis Trading Down 0.2%

Shares of EXEL opened at $38.57 on Friday. The business's 50 day moving average is $38.62 and its 200 day moving average is $39.91. The company has a market capitalization of $10.38 billion, a PE ratio of 18.54, a price-to-earnings-growth ratio of 0.80 and a beta of 0.38. Exelixis has a 12-month low of $25.17 and a 12-month high of $49.62.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.12. The company had revenue of $568.26 million for the quarter, compared to the consensus estimate of $574.36 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The firm's quarterly revenue was down 10.8% on a year-over-year basis. During the same quarter last year, the company earned $0.84 EPS. Exelixis has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Exelixis

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Truist Financial Corp lifted its holdings in shares of Exelixis by 1.1% in the 2nd quarter. Truist Financial Corp now owns 22,292 shares of the biotechnology company's stock worth $983,000 after buying an additional 250 shares during the period. Police & Firemen s Retirement System of New Jersey lifted its holdings in shares of Exelixis by 0.3% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 102,581 shares of the biotechnology company's stock worth $4,521,000 after buying an additional 274 shares during the period. Frank Rimerman Advisors LLC lifted its holdings in shares of Exelixis by 4.7% in the 1st quarter. Frank Rimerman Advisors LLC now owns 6,342 shares of the biotechnology company's stock worth $234,000 after buying an additional 285 shares during the period. Farther Finance Advisors LLC lifted its holdings in shares of Exelixis by 6.1% in the 1st quarter. Farther Finance Advisors LLC now owns 5,372 shares of the biotechnology company's stock worth $195,000 after buying an additional 307 shares during the period. Finally, Rathbones Group PLC lifted its holdings in shares of Exelixis by 5.3% in the 1st quarter. Rathbones Group PLC now owns 6,847 shares of the biotechnology company's stock worth $253,000 after buying an additional 347 shares during the period. Hedge funds and other institutional investors own 85.27% of the company's stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.